The Simons Foundation has agreed to fund the development of 5 IPSC cell lines for preclinical drug testing. We are thankful for the generosity and support of this foundation which is committed to better understanding genetic neurodevelopmental conditions.
ACCT is pushing full steam ahead to lay the necessary groundwork to appeal to the FDA for a human clinical trial.